+1 (713) 400-6400
3200 Southwest Fwy #2240 Phoenix TowerHouston, TX 77027
© 2020 Marker Therapeutics, Inc.
TapImmune, Inc. (NASDAQ: TPIV) announced today it has successfully completed a multi-gram scale-up and GMP manufacturing of a second clinical lot of TPIV 200, the company’s multi-epitope T-cell vaccine targeting folate receptor alpha.
Get Marker News Delivered To Your Inbox